Gaucher’s disease type 3 C: Unusual cause of intracardiac calcification

Gaucher’s disease type III C: Unusual cause of intracardiac calcification
Sejal Shah, Amit Misri, Meenakshi Bhat, Sunita Maheshwari
 Departments of Pediatric Cardiology and Genetics, Narayana Hrudayalaya Institute of Medical Sciences, Bangalore, India

ABSTRACT:
We report a case of intracardiac calcification associated with oculomotor apraxia and corneal deposits in a 12-year-old girl, who presented with dyspnea on exertion, sinusitis, and epistaxis since the age of 6 years. Unusual presentation with multiorgan involvement prompted us to evaluate her in terms of metabolic/storage disorder. The bone marrow aspirate confirmed the diagnosis of Gaucher’s disease.

INTRODUCTION:
Gaucher’s disease is the most common lipid-storage disorder with an autosomal recessive pattern of inheritance. It is characterized by deposition of glucocerebrosides in various organs due to deficiency of the enzyme glucocerebrosidase. Type III C has been recently identified, and classically, has cardiac valvular manifestations, unlike other forms of Gaucher’s disease. We report this rare case wherein the diagnosis was difficult due to unusual clinical manifestations. Presence of intracardiac calcification on echocardiography prompted detailed clinical and laboratory evaluation that eventually led us to the diagnosis of type III C Gaucher’s disease.

CASE REPORT:
A 12-year-old girl, born to consanguineous parents, came to the hospital seeking medical treatment for easy fatigability, dyspnea on exertion, and decreased activity for last 6 months. She also had history of recurrent episodes of sinusitis, epistaxis, and involuntary movements of upper limbs. Similar complaints were observed in one of her maternal first cousin sisters, also born to consanguineous parents, aged 8 years. She had normal growth parameters, intellect, and appearance. Clinical examination revealed pes cavus, blood pressure of 100/60 mm/Hg, and oxygen saturation of 100%. Auscultation of the chest revealed coarse crepitations bilaterally. Restricted movements of both eyeballs in specific directions were observed. Cardiac auscultation revealed normal heart sounds with a 2/6 systolic murmur at the apex and left upper sternal border.

Her chest X-ray revealed cardiothoracic ratio of 50% with no evidence of calcification. The lung fields were clear. Echocardiogram showed calcification of endocardium, mitral and aortic valves, and aortic root [Figure 1]. There was moderate mitral regurgitation, mild mitral stenosis, and mild aortic regurgitation. Calcification was also seen surrounding the aortic arch. Fluoroscopy confirmed calcification in the aortomitral area [Figure 2] and around the aortic arch and arch vessels. Thoracic CT scan revealed cardiac calcification [Figure 3A] and [Figure 3B], branch pulmonary artery dilatation, and mild compression of left upper bronchus due to dilated left pulmonary artery with left upper lobe and lingular consolidation. To look for other sites of calcification, a head CT scan was done and it showed linear calcification of right globus pallidus [Figure 4] with evidence of sinusitis. Ophthalmic evaluation revealed oculomotor apraxia with corneal dot-like intrastromal deposits. Abdominal sonography showed mild splenomegaly. A bone marrow aspirate performed confirmed the diagnosis of Gaucher’s disease [Figure 5]. The cousin sister with similar complaints was also evaluated and found to have intracardiac calcification, oculomotor apraxia, corneal opacities, and splenomegaly. Homozygous D409H mutations were confirmed in both the cousin sisters. The result of enzyme analysis to evaluate fibroblast beta glucocerebrosidase activity is awaited.

DISCUSSION:
Intracardiac calcification is commonly known to occur in rheumatic heart disease, myocardial infarction, pseudohypoparathyroidism, end-stage renal disease on chronic hemodialysis, endomyocardial fibrosis, and pseudoxanthoma elasticum. The heart is not frequently involved in Gaucher’s disease.

Type III Gaucher’s disease is a late onset, slowly progressive, subacute/chronic disorder presenting with anorexia, respiratory problems, hepatosplenomegaly, seizures, impaired coordination, and disorder of extraocular movements. Most of the patients perish before their thirtieth birthday. Type III A is characterized by myoclonus and dementia, while III B has early onset of isolated horizontal supranuclear gaze palsy with aggressive systemic illness. Type III C is associated with cardiovascular manifestations. Presence of intracardiac calcification in Gaucher’s III C has been reported.  The sites involved are mitral and aortic valves, ascending aorta, aortic arch, and coronary ostia. The calcification in our case had similar distribution, except for the involvement of coronary ostia. Veinot et al., first documented the presence of Gaucher cells in the heart valve tissue and proposed a cell-mediated mechanism involving bone matrix proteins and integrins in the pathogenesis of the valvular injury. 

The characteristic late onset of presentation with slower progression of complaints in a child born to consanguineous parents, with similar symptoms in a cousin sister, with mild splenomegaly, involuntary movements of the extremities, intracerebral calcifications, oculomotor apraxia with corneal deposits, and cardiovascular calcification made us suspect Gaucher’s disease type III C and prompted us to perform a bone marrow aspirate.

In all cases reported till date, there is homozygosity for an asp409his (D409H) mutation in the gene encoding acid beta-glucosidase located on chromosome 1q21.  This mutation was found in both the cousin sisters. Disordered intracellular trafficking of glucocerebrosidase is seen with this mutation. Treatment options include enzyme replacement therapy (ERT) and bone marrow transplantation. ERT has been described to improve hematological parameters and organomegaly. Our patient was advised ERT, but could not afford it.

Affected individuals need close monitoring to decide about the need and timing for valve replacement. Surgery is usually offered to those individuals who have clinically and hemodynamically significant valve lesion.   Apart from the valve replacement, patients have been subjected to replacement of the ascending aorta and the aortic arch with a Dacron graft when there is a significant calcification resulting in severe narrowing of the aorta. When coronary ostia are involved, one needs to graft the coronary arteries as well.

In conclusion, patients with intracardiac calcification and multiorgan involvement should be investigated for metabolic disorders such as Gaucher’s disease as was the case in our patient.

Cerebrospinal fluid β-glucocerebrosidase activity …

Cerebrospinal fluid β-glucocerebrosidase activity is reduced in dementia with lewy bodies

Section of Neurology, University of Perugia, Italy
IRCCS Fondazione S. Lucia, Rome, Italy
Section of Applied Biochemistry, University of Perugia, Italy
Dept. of Nephrology, Foligno S.Giovanni Battista Hospital, Perugia, Italy

Received 25 February 2009; 

accepted 7 March 2009. 

Available online 20 March 2009.
Abstract

The autophagy-lysosomal degradation pathway plays a role in the onset and progression of neurodegenerative diseases. Clinical and genetic studies indicate that mutations of β-glucocerebrosidase represent genetic risk factors for synucleinopathies, including Parkinson’s Disease (PD) and Dementia with Lewy Bodies (DLB). We recently found a decreased activity of lysosomal hydrolases, namely β-glucocerebrosidase, in cerebrospinal fluid of PD patients. We have thus measured the activity of these enzymes – α-mannosidase (EC 3.2.1.24), β-mannosidase (EC 3.2.1.25), β-glucocerebrosidase (EC 3.2.1.45), β-galactosidase (EC 3.2.1.23) and β-hexosaminidase (EC 3.2.1.52) – in cerebrospinal fluid of patients suffering from DLB, Alzheimer’s Disease (AD), Fronto-Temporal Dementia (FTD) and controls. Alpha-mannosidase activity showed a marked decrease across all the pathological groups as compared to controls. Conversely, β-glucocerebrosidase activity was selectively reduced in DLB, further suggesting that this enzyme might specifically be impaired in synucleinopathies.

Neuraltus Pharmaceuticals Funding for a Gaucher’s Disease drug?

I’m going to work to contact this company and see if I can get more details if this applies to GD2 or GD3!

MENLO PARK, CA–(Marketwire – March 26, 2009) – Neuraltus Pharmaceuticals, Inc., a privately held pharmaceutical company developing proprietary small molecule drugs for neurodegenerative diseases, today announced the completion of $17 million in Series A financing.

Co-investing in the Series A funding are Latterell Venture Partners of San Francisco, CA, VantagePoint Venture Partners of San Bruno, CA and Adams Street Partners of Chicago, IL. Dr. James Woody of Latterell, Annette Bianchi of VantagePoint and Terry Gould of Adams Street will join the Neuraltus Board of Directors.

Neuraltus was founded in 2005 by Michael McGrath, MD, PhD, Professor of Laboratory Medicine at the University of California, San Francisco, Edgar Engleman MD, Professor of Medicine and Pathology at Stanford University School of Medicine and Ari Azhir, PhD.

“Neuraltus offers a strong pipeline of compounds for the treatment of serious neurological diseases for which there are few if any clinical options,” said Dr. James Woody of Latterell Venture Partners.

“It is a great vote of confidence when investors with so much experience in biotechnology have chosen to devote their resources to Neuraltus,” said Ari Azhir, CEO and co-founder.

Neuraltus has a number of compounds in the pipeline, including a drug to treat ALS (Amyotropic Lateral Sclerosis, also known as Lou Gehrig’s Disease), a drug that will reduce dyskinesia (jerky involuntary movement) in patients suffering from Parkinson’s Disease, and a drug for the treatment of Gaucher’s Disease (a Lysosomal Storage Disorder). The Series A funding will enable Neuraltus to conduct and complete phase I and phase II clinical trials for each of these disorders.

“We believe Neuraltus has the potential to develop innovative drugs for these intractable diseases,” said Annette Bianchi of VantagePoint.

Gaucher’s Disease is the most prevalent Lysosomal Storage Disorder and results from a specific enzyme deficiency in the body, caused by a genetic mutation received from both parents. The disease is progressive, incurable and causes severe disability and death.

Neuronopathic Gaucher’s Disease symptoms explained

I came across this website this morning, and the information was so easy to understand, that I thought I would share it.  They also have a pamphlet which is great to print out and send to people.

The key symptoms of Type 3 NGD:

Eye Movements
Imagine you are standing at the side of a road, watching the cars go past. Normally you would fix on a car, follow it until it moved out of your field of vision, then your eyes would flick quickly back and fix on another car, and so on. So your eyes would make a slow movement, followed by a quick movement. You would be able to do this without moving your head. The movements of the eyes are called saccades, and the combination of the quick and slow movements is called nystagmus. 

In NGD, the ability to initiate the quick movements is lost. Slow movements are unaffected. So, to use the cars-on-the-road parallel, the eyes follow the first car till it moves out of the field of vision, then stay ‘locked’ in that position. The ability to flick quickly back to fix on the next car is lost.  This is what Hannah has developed so far in terms of symptoms.

To compensate for this, sufferers develop a habit of blinking in order to ‘unlock’ and then thrusting their head sideways to look at the next object. This is not seen in young children, who have not developed the habit. Older children and adults become quite expert at this, and as a result, the eye movement problem may be much less obvious. This may give the impression that the eye movements get better as the child gets older. However, there is no evidence that they do actually improve.

There are many terms that have been used for this, such as ‘oculomotor apraxia’, ‘saccade initiation failure’ etc. It is invariably the first visible sign of type 3 NGD. It is therefore very important not to miss it, since the diagnosis of NGD often hinges on it. Sometimes it can appear when a child is as young as six months.

It is usually possible for someone with experience of NGD to pick this up on clinical examination alone, although it can be difficult in certain circumstances. For example:

* In young children, who may not be very co-operative
* Soon after the initial diagnosis of Gaucher Disease is made, when the child may be too ill to co-operate
* In patients with very mild disease, regardless of their age.
* In such situations the use of special equipment may be necessary in order to make the diagnosis. However, such equipment is not widely available.

Horizontal eye movement is always affected first. For some children, vertical eye movements may be affected as well. It is not clear why horizontal movement should be affected before vertical movement.

How does this affect my child’s day-to-day activities?
There are several practical problems that may arise as a result of these abnormal eye movements.

Your child will be unable to look from side to side quickly, and so is particularly vulnerable in a crowd. This is especially relevant in a crowded playground. He or she may get inadvertently knocked over.

Your child’s ability to cross the road may be severely affected, as he or she will be unable to look quickly from side to side for approaching vehicles.

There are also significant educational issues. These are discussed more fully in the companion booklet to this one; Neuronopathic Gaucher Disease; Special Educational Needs.

——————————————–

Audiology
It is important that your child’s hearing is carefully checked. Most children appear to have normal hearing. However, many parents have noticed that in spite of a normal hearing test, their child does not seem to hear very well. Some children take a little longer to respond to questions, although eventually they give the right answer. In other words, they seem to have a problem with processing. They also seem to have problems hearing what is said to them against a background noise. This is known as cocktail party syndrome.

Research is under way to find out exactly why this should be the case. One area that is being investigated is the brainstem. The test used is the brainstem auditory evoked response (BAER). There are standardised ways of doing this. Usually, a series of clicks is emitted through headphones placed over the child’s ears, and the response is read through special electrodes placed over the scalp. Normally, a trace is obtained showing several waves. These waves have a distinctive shape and occur at certain intervals. Although people initially believed that each step in the hearing pathway is represented by a wave, the real situation is probably far more complex, so interpreting the result can be quite difficult.

What is clear is that these waveforms are more severely affected in Type 2 than Type 3. However, within each group the pattern is not so clear. Also it is not yet clear how useful the test is in monitoring disease progression. Although there is evidence that the waveform may get less distinct as the child grows older, there is no clear evidence that this means that the disease is progressing.

It should be emphasized that the BAER is not a hearing test. Its function is to test the pathways within the brain. A proper hearing test should always be performed. In fact, if there are any abnormalities in the BAER, they can be interpreted accurately only if a hearing test has been performed.

How does this affect my child’s day-to-day activities?
Even if the peripheral hearing is normal, there may be problems. If your child suffers from cocktail party syndrome, his or her ability to understand what is being said, particularly against a noisy background – for example, in the playground or a noisy classroom – may be affected. This, together with the processing problem mentioned above, may give the impression that he or she is very slow to respond to questions or instructions.

——————————————-

Movement Disorders
Problems with posture and movement can be seen in Gaucher Disease. The most common of these is Parkinson’s disease. It has been thought for some time that Parkinsonian symptoms are more common in people with Gaucher Disease. They are different from those seen in otherwise normal people in that they occur at a younger age, are more severe and are more resistant to therapy. Initially it was thought that they might be part of NGD. However, these symptoms occur in type I sufferers as well. Most people now believe that these symptoms are not true manifestations of NGD, but that Gaucher disease sufferers are more likely to develop Parkinsonian symptoms.

Other movement disorders have been observed as well. Because of this, there has been a lot of recent interest in the basal ganglia. These are the nerve centres in the brain that control posture and movement. If they are affected, potential problems include:

Changes in tone (floppiness, rigidity)
Abnormal movements (tics, tremor)
Problems with balance (ataxia).
Further research is needed to clarify these issues.

How does this affect my child’s day-to-day activities?
This will vary depending on the nature and degree of the movement disorder.

——————————————-

Other Problems
NGD sufferers may have quite severe visceral disease (visceral refers to involvement of the viscera or the chest and abdominal organs). Especially in small children, the abdominal distension caused by the enlarged liver and spleen may be so great as to push upwards on the diaphragm. This can cause quite significant breathing difficulties, and may also cause feeding problems.

The spine is invariably involved. A generalized curvature (kyphosis) is seen in nearly all sufferers. The reason for this is not quite clear.

Lung disease is extremely common and may cause breathing problems, a troublesome cough and chest infections. These are thought to be due to the presence of Gaucher cells in the lungs.

Sufferers may feel extremely tired. There may be more than one reason for this, such as lung involvement or spinal involvement. However, in many cases there is no obvious cause. There is no doubt though that it can be quite significant.

Jordell…The beginning

Guest post by Nichole, Mom to Jordell with Gaucher’s Disease type 3

jordellJordell was always a normal little boy but seemed to have a big tummy and was sick alot. All the doctors said it was normal and he would just grow into his tummy. When he went for his 18 month check up I asked the doctor once again and he felt it and knew that something wasnt right so Jordell had an ultrasound 2 days later and they found out he had a very massive spleen. They got him into Blank Childern’s Hospital in Des Moines, Iowa.

They wanted to wait a few months but when I got on the computer and looked why someone would have an enlarged spleen everything pointed to leukemia. As any worried mother would do I fought my hardest to get him in as soon as possible so they got ahold of the doctor and wanted to see him the next day. So we traveled the 2 hours that night and got right in the next morning.

They did a bone marrow biopsy and the doctor told me that we wouldnt go home untill he could tell me whats wrong with him. So went had to stay in the hospital and I was very nervous all day and finally he came in and told me that Jordell had leukemia, my heart sank. Right away we started talking about Chemotherapy. Jordell had surgery on Feburary 22, 2008 to have a port placed in his chest and got a dose of interthecal chemotherapy. He was going to start Chemo that night but then the doctor came in and said they didnt think he had leukemia.

After that they ran more tests and everything came back negitive. The doctor then got ahold of another doctor in Rochester, Minnesota and thought they could find out what was wrong so we went by ambulance 3 and a half hours in the snow and ice. That was not a fun ride! When we got there, right away they started running more tests. I have never seen so many doctors in my life, I think there was every kind of doctor you could ever think of come in and out of his room. They decided to send us home since in was Friday and they couldnt really do much over the weekend but we had to come back Monday. But we were very excited to go home and sleep in our own beds for a couple nights!!

So we went back Monday and did some more tests and found out other ones came back negative. Still confused about whats going on. We went home Tuesday the 4th and had an appointment for Friday the 14th set up in Iowa City, Iowa and hopefully by then we would know what it was that was wrong.

On March 13th I got a call that said Jordell had Gaucher Disease. They werent sure what type yet but I was relived to have a diagnosis but also scared because I didnt know much about Gaucher Disease. Thankfully we went to Iowa City the next day!

Learning some interesting possibilities

I found out some really interesting information about a possible treatment assistance (not a full treatment) today regarding a pharmacological chaperone concept.  I’ll share more of the details once they go public.  However, after learning more, it may not be advantageous for Hannah because of her level of enzyme production, but I’m still going to see how this plays out.

It is good to know what is going on out there.

I have only found two researcher groups so far that are looking into GD2 and GD3.  I’m still looking though!